0001437749-24-012331.txt : 20240417
0001437749-24-012331.hdr.sgml : 20240417
20240417162118
ACCESSION NUMBER: 0001437749-24-012331
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240417
FILED AS OF DATE: 20240417
DATE AS OF CHANGE: 20240417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schoen Eric
CENTRAL INDEX KEY: 0001532303
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41905
FILM NUMBER: 24851331
MAIL ADDRESS:
STREET 1: 7801 N. CAPITAL OF TX HWY
STREET 2: SUITE 260
CITY: AUSTIN
STATE: TX
ZIP: 78731
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CASSAVA SCIENCES INC
CENTRAL INDEX KEY: 0001069530
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 911911336
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6801 N CAPITAL OF TEXAS HIGHWAY
STREET 2: BUILDING 1; SUITE 300
CITY: AUSTIN
STATE: TX
ZIP: 78731
BUSINESS PHONE: 512-501-2444
MAIL ADDRESS:
STREET 1: 6801 N CAPITAL OF TEXAS HIGHWAY
STREET 2: BUILDING 1; SUITE 300
CITY: AUSTIN
STATE: TX
ZIP: 78731
FORMER COMPANY:
FORMER CONFORMED NAME: PAIN THERAPEUTICS INC
DATE OF NAME CHANGE: 20000309
4
1
rdgdoc.xml
FORM 4
X0508
4
2024-04-17
0001069530
CASSAVA SCIENCES INC
SAVA
0001532303
Schoen Eric
6801 N CAPITAL OF TEXAS HWY, BLDG 1
SUITE 300
AUSTIN
TX
78731
1
Chief Financial Officer
0
Common Stock
2024-04-17
4
M
0
1500
22
A
21300
D
Common Stock
2000
I
By limited liability corporation
Common Stock Warrant
33
2024-01-03
4
A
0
7920
0
A
2024-01-03
2024-05-07
Common Stock
11880
7920
D
Common Stock Warrant
33
2024-01-03
4
A
0
800
0
A
2024-01-03
2024-05-07
Common Stock
1200
800
I
By limited liability corporation
Common Stock Warrant
33
2024-04-17
4
M
0
1000
0
D
2024-01-03
2024-05-07
Common Stock
1500
6920
D
Form 4 represents exercise for cash of common stock warrants received on January 3, 2024. Holder received one and one-half shares of common stock for each common stock warrant exercised.
Represents warrants that were originally issued on January 3, 2024 as a pro-rata distribution to all holders of common shares. Each warrant entitles the holder to purchase one and one-half common shares at an exercise price of $33.00 per warrant. This distribution was exempt from immediate reporting under Section 16.
/s/ Eric J. Schoen
2024-04-17